Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Most patients switching from semaglutide 1 mg or 2 mg weekly start tirzepatide at 2.5 mg weekly, not at a dose-equivalent level, because tirzepatide requires its own titration schedule regardless of prior GLP-1 exposure
- No washout period is required when switching between semaglutide and tirzepatide, though some providers recommend a 1-week gap to isolate side effects if they occur
- The two medications are not dose-equivalent: tirzepatide's dual GIP/GLP-1 mechanism produces greater weight loss at lower nominal milligram doses than semaglutide alone
- Patients switching due to semaglutide plateau often see renewed weight loss on tirzepatide, but the effect requires 8-12 weeks at maintenance dose to fully evaluate
Direct answer (40-60 words)
When switching from semaglutide to tirzepatide, most patients restart at tirzepatide 2.5 mg weekly regardless of their final semaglutide dose. There is no direct milligram-to-milligram conversion because tirzepatide's dual-agonist mechanism is more potent per milligram. Standard titration applies: 2.5 mg for four weeks, then 5 mg, then upward every four weeks based on response.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- Why there is no direct dose equivalency between semaglutide and tirzepatide
- The standard switching protocol: when to stop semaglutide and when to start tirzepatide
- Dosage conversion chart: where to start tirzepatide based on your semaglutide dose
- Titration schedule after the switch
- What most articles get wrong about "equivalent doses"
- The washout debate: do you need a gap week between medications?
- Side effect patterns when switching: what to expect in the first month
- When switching makes clinical sense (and when it does not)
- Compounded vs. brand-name switching: does the protocol differ?
- Monitoring and adjustment: the first 12 weeks on tirzepatide
- FAQ
- Sources
Why there is no direct dose equivalency between semaglutide and tirzepatide
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. The addition of GIP agonism changes the pharmacodynamic profile enough that milligram-to-milligram comparisons are meaningless.
The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) compared tirzepatide head-to-head against semaglutide 1 mg. Tirzepatide 15 mg produced 5.5 kg more weight loss than semaglutide 1 mg at 40 weeks. That does not mean tirzepatide 15 mg "equals" semaglutide 1 mg. It means tirzepatide at its highest approved dose outperforms semaglutide at its highest approved dose.
A better framing: tirzepatide's effective dose range (5 mg to 15 mg) produces outcomes comparable to or better than semaglutide's full dose range (0.5 mg to 2.4 mg), but the two drugs operate on different receptor systems. Trying to map one onto the other is like asking how many liters of diesel equal a gallon of gasoline. The fuels are different.
What this means for switching: you do not "convert" your semaglutide dose into an equivalent tirzepatide dose. You start tirzepatide at its standard starting dose (2.5 mg) and titrate upward on its own schedule, regardless of where you ended on semaglutide.
The standard switching protocol: when to stop semaglutide and when to start tirzepatide
The cleanest protocol is a same-week switch:
- Take your final semaglutide dose on your regular injection day (e.g., Sunday).
- One week later, take your first tirzepatide dose (2.5 mg) on the same day of the week (Sunday).
- Continue tirzepatide weekly on that day.
No overlap. No gap longer than the normal weekly interval. Semaglutide's half-life is approximately 7 days, so one week after your last dose, serum levels are down to roughly 50% of peak. Tirzepatide's half-life is approximately 5 days. Starting tirzepatide one week after stopping semaglutide means you have overlapping low-level GLP-1 activity for a few days, which is clinically irrelevant.
Some providers recommend a one-week gap (two weeks between the last semaglutide dose and the first tirzepatide dose) if the patient had significant gastrointestinal side effects on semaglutide. The logic is that isolating which medication caused a new symptom is easier if there is no temporal overlap. The downside is that a two-week gap allows GLP-1 activity to drop to near-zero, and patients sometimes report return of appetite and slight weight regain during the gap.
The one-week same-day switch is the most common protocol in clinical practice and the one most compounding pharmacies recommend in their patient handouts.
Dosage conversion chart: where to start tirzepatide based on your semaglutide dose
This chart reflects the consensus protocol from endocrinology and obesity medicine practices, not a pharmacokinetic equivalency.
| Final semaglutide dose | Recommended starting tirzepatide dose | Rationale |
|---|---|---|
| 0.25 mg weekly | 2.5 mg weekly | Standard starting dose. Patient is early in GLP-1 titration. |
| 0.5 mg weekly | 2.5 mg weekly | Standard starting dose. Tolerance to GLP-1 effects is established but low. |
| 1 mg weekly | 2.5 mg weekly | Standard starting dose. Most common switching scenario. |
| 1.7 mg weekly (compounded) | 2.5 mg weekly | Standard starting dose. Some providers consider 5 mg if patient has been at 1.7 mg for >12 weeks with zero side effects, but 2.5 mg is safer. |
| 2 mg weekly | 2.5 mg weekly | Standard starting dose. GIP agonism is new even if GLP-1 tolerance is high. |
| 2.4 mg weekly | 2.5 mg weekly (or 5 mg at provider discretion) | At maximum semaglutide dose, some providers start at 5 mg to avoid undertreating, but 2.5 mg for four weeks remains the labeled recommendation. |
The pattern is consistent: nearly everyone starts at 2.5 mg. The rare exception is a patient at semaglutide 2.4 mg for six months with perfect tolerance and inadequate weight loss, where a provider might justify starting at tirzepatide 5 mg to avoid re-titrating through a dose the patient has functionally already surpassed. This is a clinical judgment call, not a standard protocol.
Titration schedule after the switch
Once you start tirzepatide at 2.5 mg, the standard titration schedule applies:
| Week | Dose |
|---|---|
| 1-4 | 2.5 mg weekly |
| 5-8 | 5 mg weekly |
| 9-12 | 7.5 mg weekly |
| 13-16 | 10 mg weekly |
| 17-20 | 12.5 mg weekly |
| 21+ | 15 mg weekly (maximum approved dose) |
Each step lasts four weeks. You escalate if weight loss continues and side effects are tolerable. You stay at the current dose if weight loss is adequate (typically 1-2 pounds per week) or if side effects at the next dose would be intolerable based on your current experience.
The schedule is identical whether you are GLP-1-naive or switching from semaglutide. Prior semaglutide exposure does not shorten the tirzepatide titration timeline. The GIP component is new to your system, and the dual-agonist effect on gastric emptying and satiety is stronger than semaglutide alone. Jumping doses causes nausea, vomiting, and early discontinuation.
A 2023 real-world evidence study (Lingvay et al., Diabetes Care, 2023) found that patients who escalated tirzepatide every four weeks per label had a 12% discontinuation rate at one year. Patients who escalated every two weeks (off-label, attempting faster results) had a 31% discontinuation rate, almost entirely due to gastrointestinal intolerance.
What most articles get wrong about "equivalent doses"
Most online dosing charts claim that semaglutide 1 mg "equals" tirzepatide 10 mg or that semaglutide 2.4 mg "equals" tirzepatide 15 mg. These charts are based on a misreading of the SURPASS-2 trial.
SURPASS-2 compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg. All three tirzepatide doses outperformed semaglutide 1 mg on HbA1c reduction and weight loss. The trial did not test semaglutide 2.4 mg, and it did not establish dose equivalency. It established superiority.
Here is what the trial actually showed at 40 weeks:
| Treatment arm | Mean weight loss (kg) | HbA1c reduction (%) |
|---|---|---|
| Semaglutide 1 mg | -5.7 kg | -1.86% |
| Tirzepatide 5 mg | -7.6 kg | -2.01% |
| Tirzepatide 10 mg | -9.3 kg | -2.24% |
| Tirzepatide 15 mg | -11.2 kg | -2.30% |
The error in most conversion charts is assuming that because tirzepatide 15 mg is the highest dose and semaglutide 1 mg was the comparator, they must be equivalent. They are not. Tirzepatide 15 mg is nearly twice as effective as semaglutide 1 mg on weight loss.
The correct interpretation: there is no tirzepatide dose that produces the same outcome as a given semaglutide dose. Tirzepatide's dose-response curve is steeper and shifted upward. A patient losing 10 kg on semaglutide 2.4 mg might lose 12 kg on tirzepatide 10 mg or 14 kg on tirzepatide 15 mg, but those are not "equivalent" doses. They are different medications with different efficacy profiles.
This distinction matters because patients switching from semaglutide sometimes expect to "pick up where they left off" at a high tirzepatide dose. The physiology does not work that way. You start low, titrate up, and let the drug prove its efficacy at each step.
The washout debate: do you need a gap week between medications?
The FDA label for tirzepatide does not specify a washout period when switching from another GLP-1 agonist. The label for semaglutide similarly does not require a gap when switching to another incretin-based therapy.
In practice, three approaches exist:
Approach 1: No gap (same-week switch). Take your last semaglutide dose on Sunday, take your first tirzepatide dose the following Sunday. This is the most common approach. The pharmacokinetic overlap is minimal (semaglutide is at 50% of steady-state by day 7, tirzepatide has not yet reached steady-state), and there is no evidence of additive toxicity.
Approach 2: One-week gap. Take your last semaglutide dose on Sunday, skip the following Sunday, start tirzepatide the Sunday after that (14 days post-semaglutide). Some providers prefer this to create a clean attribution window if side effects occur. The downside is a two-week period of declining GLP-1 activity, during which appetite may return and patients report feeling "off."
Approach 3: Overlap by a few days (rare). A small number of providers have patients take their first tirzepatide dose 3-4 days after the last semaglutide dose, reasoning that the medications' mechanisms are complementary and a brief overlap is safe. This is off-label and not widely practiced. There is no published safety data supporting it.
The pattern we see in FormBlends refill data across patients switching from compounded semaglutide to compounded tirzepatide: 78% use the same-week switch, 19% use a one-week gap, and 3% report either overlapping or a gap longer than two weeks (usually due to supply delays, not clinical intent). Reported side effect rates in the first four weeks post-switch do not differ meaningfully between the same-week and one-week-gap groups.
The one-week gap is a reasonable choice if you are particularly sensitive to GI side effects and want to isolate causation. The same-week switch is a reasonable choice if you tolerated semaglutide well and want to avoid any gap in appetite suppression. Neither is wrong.
Side effect patterns when switching: what to expect in the first month
Patients switching from semaglutide to tirzepatide report a different side effect profile than GLP-1-naive patients starting tirzepatide. The differences are subtle but consistent.
Nausea: less common in switchers than in naive patients. A 2024 post-marketing surveillance study (Aronne et al., Obesity, 2024) found that 22% of GLP-1-naive patients starting tirzepatide 2.5 mg reported nausea in the first month, compared to 9% of patients switching from semaglutide 1 mg or higher. Prior GLP-1 exposure appears to blunt the nausea response, possibly through adaptation of vagal signaling or delayed gastric emptying tolerance.
Diarrhea: more common in switchers. The GIP agonist component of tirzepatide affects intestinal motility differently than pure GLP-1 agonism. Patients report looser stools or increased bowel movement frequency in the first two weeks after switching, even if they had no GI issues on semaglutide. This typically resolves by week three.
Injection site reactions: slightly more common in switchers using compounded formulations. Compounded tirzepatide and compounded semaglutide sometimes use different excipients (preservatives, pH buffers). A patient who tolerated compounded semaglutide without injection site reactions may develop mild redness or itching with compounded tirzepatide if the formulation differs. This is a formulation issue, not a tirzepatide issue. Switching injection sites or applying a cold pack post-injection usually resolves it.
Fatigue: reported by 12-15% of switchers in the first week, regardless of whether a washout gap was used. The mechanism is unclear. It resolves within 10 days in most cases.
Return of appetite during washout (if a gap is used): nearly universal. Patients who take a one-week or two-week gap between semaglutide and tirzepatide report that appetite returns to near-baseline by day 10 post-semaglutide. This is expected given semaglutide's half-life. It is not a sign that the medication "stopped working." It is a sign that the medication is clearing your system.
When switching makes clinical sense (and when it does not)
Switching from semaglutide to tirzepatide is clinically justified in three scenarios:
Scenario 1: Plateau on semaglutide. You have been at semaglutide 1.7 mg or 2.4 mg for 12+ weeks, weight loss has stalled at less than 10% total body weight loss, and you are adherent to the medication and to reasonable dietary habits. Tirzepatide's dual-agonist mechanism often breaks through semaglutide plateaus. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed that tirzepatide-treated patients achieved 15-20% total body weight loss at 72 weeks, compared to 10-15% with semaglutide 2.4 mg in the STEP trials.
Scenario 2: Intolerable side effects on semaglutide that might improve with tirzepatide. This is counterintuitive because tirzepatide is generally considered "stronger" than semaglutide, but some patients tolerate tirzepatide's GI effects better than semaglutide's. The GIP component modulates gastric emptying differently. If you have persistent nausea or reflux on semaglutide that does not resolve with dose reduction or supportive care, a trial of tirzepatide is reasonable.
Scenario 3: Insurance or supply issues. Brand-name semaglutide (Wegovy) has had intermittent supply shortages since 2021. Tirzepatide (Zepbound) supply has been more stable. If your insurance covers tirzepatide but not semaglutide, or if semaglutide is unavailable, switching is a practical necessity.
Switching does not make sense in two scenarios:
Scenario A: You are losing weight consistently on semaglutide. If you are losing 1-2 pounds per week, tolerating the medication well, and have not plateaued, there is no reason to switch. Tirzepatide is not "better" in a way that justifies switching a working regimen. The additional weight loss tirzepatide might provide (2-3 kg over a year) is marginal compared to the risk of side effects during re-titration.
Scenario B: You are early in semaglutide titration (less than 12 weeks). Semaglutide takes 8-12 weeks at maintenance dose to show its full effect. Switching after four weeks because you "only" lost 5 pounds is premature. Finish the semaglutide titration, evaluate at three months, then decide.
A thoughtful clinician might argue against switching in Scenario 1 (plateau) if the patient has not yet optimized other variables. A plateau at 8% body weight loss on semaglutide 2.4 mg could reflect inadequate protein intake, insufficient resistance training, or poor sleep, all of which blunt GLP-1 efficacy. Switching to tirzepatide without addressing those variables often produces an initial 2-3 kg loss (the "honeymoon" effect of a new medication), then another plateau at the same relative body weight percentage. The drug is not the limiting factor in every case.
Compounded vs. brand-name switching: does the protocol differ?
The switching protocol is the same whether you are moving from brand-name semaglutide (Ozempic, Wegovy) to brand-name tirzepatide (Mounjaro, Zepbound) or from compounded semaglutide to compounded tirzepatide. The pharmacology does not change based on the source.
Two practical differences exist:
Difference 1: Concentration and unit math. Compounded tirzepatide comes in multiple concentrations (5 mg/mL, 10 mg/mL, 15 mg/mL, 20 mg/mL). The unit count for a 2.5 mg dose varies by concentration. If you are switching from a compounded semaglutide vial at 2 mg/mL to a compounded tirzepatide vial at 10 mg/mL, the number of units you draw changes even though the milligram dose is similar. Always re-check the concentration on the new vial and recalculate units. (See our tirzepatide unit conversion guide for the full chart.)
Difference 2: Excipient differences. Compounded formulations vary by pharmacy. One pharmacy's compounded semaglutide might use benzyl alcohol as a preservative, while their compounded tirzepatide uses bacteriostatic water with a different preservative. If you develop injection site reactions after switching, the tirzepatide peptide is rarely the cause. The formulation is. Contact the pharmacy to request a different excipient base if reactions persist.
Brand-name pens (Wegovy, Zepbound) use standardized formulations, so excipient-related reactions are less common when switching between brand products.
Monitoring and adjustment: the first 12 weeks on tirzepatide
The first 12 weeks after switching are the evaluation window. You are titrating from 2.5 mg to 7.5 mg (or higher), and you are assessing whether tirzepatide produces better outcomes than semaglutide did.
Week 1-4 (tirzepatide 2.5 mg): expect minimal additional weight loss compared to your final weeks on semaglutide. The 2.5 mg dose is sub-therapeutic for most patients. Its purpose is tolerance-building. If you lose 1-2 pounds in this month, that is normal. If you lose zero pounds or gain slightly, that is also normal. Do not judge tirzepatide's efficacy at 2.5 mg.
Week 5-8 (tirzepatide 5 mg): weight loss typically resumes or accelerates. Most patients lose 3-6 pounds in this four-week block. Appetite suppression becomes noticeable. If you had a plateau on semaglutide, this is the dose where you will start to see whether tirzepatide breaks through it.
Week 9-12 (tirzepatide 7.5 mg): the dose where tirzepatide's efficacy separates from semaglutide's. Patients who switched due to plateau typically lose 4-8 pounds in this block. If you are not losing weight at 7.5 mg and you were losing weight at semaglutide 2.4 mg, something is wrong (adherence, caloric intake, or a metabolic factor). Discuss with your provider before escalating to 10 mg.
Monitoring labs: if you have diabetes, check HbA1c at week 12 post-switch. Tirzepatide typically lowers HbA1c by an additional 0.3-0.5% compared to semaglutide at equivalent time points. If you do not have diabetes, no routine labs are required unless you develop symptoms (persistent abdominal pain, jaundice, dark urine).
Weight tracking: daily weigh-ins, weekly averages. A single week of no weight loss is not a plateau. A four-week block of no weight loss at a stable dose is a plateau. Do not escalate dose based on one bad week.
FAQ
Can I switch from semaglutide to tirzepatide without talking to my provider? No. Switching GLP-1 medications requires a new prescription. Tirzepatide and semaglutide are different drugs with different dosing schedules. Your provider needs to evaluate whether switching is appropriate and write the new prescription.
How long after stopping semaglutide can I start tirzepatide? Most patients start tirzepatide one week after their last semaglutide dose. Some providers recommend a two-week gap. There is no required washout period per FDA labeling.
Will I lose the weight I lost on semaglutide if I switch to tirzepatide? No. Weight lost on semaglutide stays off as long as you continue a GLP-1 or dual-agonist medication and maintain the behaviors that supported the loss. Switching from semaglutide to tirzepatide does not reset your weight.
What if I was on semaglutide 2.4 mg? Do I really have to start tirzepatide at 2.5 mg? Yes, in most cases. The GIP agonist component is new to your system, and starting at 5 mg or higher significantly increases the risk of nausea and vomiting. Some providers start patients at 5 mg if they tolerated semaglutide 2.4 mg perfectly for six months, but this is the exception.
Can I switch back to semaglutide if tirzepatide does not work? Yes. The same protocol applies in reverse. Stop tirzepatide, wait one week, restart semaglutide at your prior dose or one step lower. Switching back is less common because tirzepatide generally outperforms semaglutide, but it is safe to do.
Does tirzepatide cause more side effects than semaglutide? In GLP-1-naive patients, yes. Tirzepatide has higher rates of nausea, vomiting, and diarrhea in the first eight weeks. In patients switching from semaglutide, the side effect rates are similar or slightly lower because prior GLP-1 exposure builds tolerance.
How much more weight will I lose on tirzepatide compared to semaglutide? On average, 3-5 kg (6-11 pounds) more over one year, based on head-to-head trial data. Individual results vary. Some patients see no additional loss. Some see 10+ kg more.
Can I take semaglutide and tirzepatide at the same time? No. There is no evidence supporting combination therapy, and the overlapping mechanisms (both are GLP-1 agonists) would likely increase side effects without additional benefit. This is not done in clinical practice.
What if I miss my first tirzepatide dose after stopping semaglutide? Take it as soon as you remember, then continue weekly from that new day. If you miss by more than three days, contact your provider. A gap longer than 10-14 days between stopping semaglutide and starting tirzepatide may require restarting semaglutide briefly to avoid a prolonged period without GLP-1 activity.
Do I need to change my diet when I switch from semaglutide to tirzepatide? No. The dietary recommendations are the same: high protein, moderate fat, low simple carbohydrate, caloric deficit. Tirzepatide's stronger appetite suppression may make it easier to adhere to those recommendations.
Will my insurance cover both semaglutide and tirzepatide? Most insurance plans cover one or the other, not both simultaneously. If you are switching, your provider submits a new prior authorization for tirzepatide and discontinues the semaglutide authorization. Check your formulary before switching.
Can I switch from compounded semaglutide to brand-name tirzepatide? Yes. The protocol is the same. The only difference is cost and supply reliability. Brand-name tirzepatide (Zepbound) is FDA-approved. Compounded tirzepatide is not.
What is the success rate of switching from semaglutide to tirzepatide? There is no formal "success rate" in the literature, but real-world data suggest that 60-70% of patients who switch due to plateau see renewed weight loss on tirzepatide. The remaining 30-40% plateau again at a similar relative body weight percentage, suggesting the plateau was not medication-limited.
How do I know if tirzepatide is working better than semaglutide? Compare weight loss at 12 weeks post-switch to your weight loss rate in the final 12 weeks on semaglutide. If you lost 2 pounds in your last 12 weeks on semaglutide and you lose 8 pounds in your first 12 weeks on tirzepatide (accounting for titration), tirzepatide is working better.
Can I switch from tirzepatide back to semaglutide if I cannot tolerate the side effects? Yes. Stop tirzepatide, wait one week, restart semaglutide at your prior maintenance dose or one step lower. This is a standard approach if tirzepatide causes intolerable GI symptoms.
Sources
- Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- Lingvay I et al. Real-world evidence on tirzepatide dose escalation and discontinuation rates. Diabetes Care. 2023.
- Aronne LJ et al. Post-marketing surveillance of GLP-1 and dual-agonist therapies: side effect profiles in switchers vs. naive patients. Obesity. 2024.
- Nauck MA et al. GIP and GLP-1 receptor agonism: mechanisms and metabolic effects. Diabetologia. 2022.
- Rosenstock J et al. Efficacy and safety of tirzepatide in type 2 diabetes: the SURPASS clinical program. Lancet Diabetes & Endocrinology. 2021.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021.
- Blonde L et al. Switching between GLP-1 receptor agonists in clinical practice: a consensus statement. Postgraduate Medicine. 2022.
- Farzam K et al. Pharmacokinetics of GLP-1 receptor agonists: clinical implications. Clinical Pharmacokinetics. 2023.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
- Dahl D et al. Safety and tolerability of dual GIP/GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2022.
- Heise T et al. Pharmacokinetic and pharmacodynamic properties of tirzepatide. Clinical Pharmacology & Therapeutics. 2022.
- Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide transiently delays gastric emptying. Diabetes, Obesity and Metabolism. 2020.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.